SCHEMBL12866145

SCHEMBL12866145

Cc1cccc2[nH]nc(Cl)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 4/20 0.51
MAPK1 P28482 2/20 0.51
MAPKAPK2 P49137 1/20 0.51
MAPK6 Q16659 1/20 0.51
GAA P10253 4/20 0.47
ADRA2A P08913 1/20 0.43
PDPK1 O15530 2/20 0.39
GPR84 Q9NQS5 1/20 0.39
CHEK1 O14757 2/20 0.37
MGAM O43451 3/20 0.37
SI P14410 3/20 0.37
MGAM2 Q2M2H8 3/20 0.37
TTK P33981 2/20 0.36
CYP1A2 P05177 2/20 0.36
KIT P10721 2/20 0.36
KDR P35968 2/20 0.36
FLT3 P36888 2/20 0.36
MAPK8 P45983 2/20 0.36
MAPK9 P45984 2/20 0.36
MAPK10 P53779 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8404437 0.79 MAPK1 (0.54) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL1172394 0.76 GAA (0.56) MAP2K4MAPK1GAAPDPK1CHEK1
SCHEMBL23604563 0.76 PDPK1 (0.52) MAP2K4MAPK1GAAPDPK1CHEK1
SCHEMBL7737026 0.76 GAA (0.47) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL14631680 0.76 MAPK1 (0.51) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL31190844 0.76 MAPK1 (0.51) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL24455090 0.76 MAPK1 (0.51) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL23206119 0.76 GAA (0.35) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL569660 0.76 GAA (0.61) MAP2K4MAPK1MAPKAPK2MAPK6GAA
SCHEMBL28445675 0.76 MAPK1 (0.60) MAP2K4MAPK1MAPKAPK2MAPK6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046108-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2011-02-24 US disclosed
US-20110046108-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046108-A1 PYRIMIDINE DERIVATIVES EPHB4, EPHB1, EPHB3 MAP2K4 737/4885MAPK1 739/4885MAPKAPK2 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.